FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Koenig Sheldon L.					2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR]								(Che	ck all applica	onship of Reporting Il applicable) Director Officer (give title		on(s) to Issu 10% Ov Other (s	wner	
	ERION TH	First) HERAPEUTICS, DRIVE, SUITE				3. Date of Earliest Transaction (Month/Day/Year) 01/28/2021								_ X	below)	hief Operating Officer			poony
(Street) ANN AF		f[[48108 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)	Form fil	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date			Date	Transaction ate Ionth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		Transaction Disposed Code (Instr.		ities Acquired (A) o			5. Amoun Securities Beneficia Owned Fo	s lly ollowing	Form	: Direct · Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(111511.4)		
Common Stock			01/2	8/2021			A		30,000 ⁽¹⁾ A		\$ <mark>0</mark>	30,000			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	ite, Ti	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported	e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)		Date Exercisabl		xpiration ate	Title	or Ni	mount umber Shares		Transacti (Instr. 4)	on(s)		
Stock Option (right to buy)	\$32.12	01/28/2021			A		150,000		(1)	0	1/28/2031	Comm		50,000	\$0	150,000		D	

Explanation of Responses:

1. Such award will vest over a four (4) year period as follows: 25% shall vest on the one year anniversary of December 15, 2020 and the remainder shall vest in equal quarterly installments over the three (3) year period thereafter, subject to continued service

Remarks:

/s/ Richard B. Bartram, by power of attorney

** Signature of Reporting Person Date

01/29/2021

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.